Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program

by rvvadmin | Apr 1, 2025 | 2025

TORONTO, April 01, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and...

Revive Therapeutics Announces Results of Annual Shareholder Meeting

by rvvadmin | Mar 19, 2025 | 2025

TORONTO, March 19, 2025 –  Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and...

Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program

by rvvadmin | Mar 3, 2025 | 2025

TORONTO, March 03, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and...

Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

by rvvadmin | Feb 3, 2025 | 2025

TORONTO, Feb. 03, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical...

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

by rvvadmin | Jan 8, 2025 | 2025

TORONTO, Jan. 08, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical...